Fulcrum Therapeutics (FULC)
(Delayed Data from NSDQ)
$9.17 USD
+0.38 (4.32%)
Updated Aug 23, 2024 04:00 PM ET
1-Strong Buy of 5 1
F Value B Growth A Momentum C VGM
Fulcrum Therapeutics, Inc. (FULC) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$16.11 | $26.00 | $5.00 | 75.68% |
Price Target
Based on short-term price targets offered by nine analysts, the average price target for Fulcrum Therapeutics, Inc. comes to $16.11. The forecasts range from a low of $5.00 to a high of $26.00. The average price target represents an increase of 75.68% from the last closing price of $9.17.
Analyst Price Targets (9 )
Broker Rating
Fulcrum Therapeutics, Inc. currently has an average brokerage recommendation (ABR) of 1.44 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by nine brokerage firms. The current ABR compares to an ABR of 1.44 a month ago based on nine recommendations.
Of the nine recommendations deriving the current ABR, seven are Strong Buy and one is Buy. Strong Buy and Buy respectively account for 77.78% and 11.11% of all recommendations. A month ago, Strong Buy made up 77.78%, while Buy represented 11.11%.
Broker Rating Breakdown
![Broker Rating Visualization](https://widget3.zacks.com/images/charts/bar/brokerage/bar/FULC.png)
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 7 | 7 | 7 | 7 | 7 |
Buy | 1 | 1 | 1 | 1 | 1 |
Hold | 0 | 0 | 0 | 0 | 0 |
Sell | 1 | 1 | 1 | 1 | 1 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.44 | 1.44 | 1.44 | 1.44 | 1.44 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
7/31/2024 | SVB Securities | Joseph P Schwartz | Strong Buy | Strong Buy |
7/19/2024 | Piper Sandler | Edward A Tenthoff | Strong Buy | Strong Buy |
5/20/2024 | Cantor Fitzgerald & Co | Kristen Kluska | Not Available | Strong Buy |
5/14/2024 | Goldman Sachs | Corinne Johnson | Hold | Strong Buy |
5/14/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
5/14/2024 | H.C. Wainwright & Co. | Andrew S Fein | Strong Buy | Strong Buy |
5/13/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
3/13/2024 | Not Identified | Not Identified | Not Available | Moderate Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.44 |
ABR (Last week) | 1.44 |
# of Recs in ABR | 9 |
Average Target Price | $16.11 |
LT Growth Rate | 56.60% |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 81 of 253 |
Current Quarter EPS Est: | -0.41 |